Arrowhead Pharmaceuticals, Inc. (ARWR) Stock
ARWR Key Statistics
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
CEO: Christopher R. Anzalone. Company website
ARWR — Frequently Asked Questions
What is the ARWR stock price today?
Arrowhead Pharmaceuticals, Inc. (ARWR) trades at $49.36, up 0.73% on the day, as of Nov 12, 2026 09:38 UTC.
What is Arrowhead Pharmaceuticals, Inc.'s market cap?
Arrowhead Pharmaceuticals, Inc. has a market capitalisation of $6.97B, calculated from the live ARWR share price and shares outstanding.
What is the P/E ratio of ARWR?
ARWR has no meaningful price-to-earnings ratio: Arrowhead Pharmaceuticals, Inc. lost $2.24 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Arrowhead Pharmaceuticals, Inc. make?
Arrowhead Pharmaceuticals, Inc. generated revenue of $669.50M over the trailing twelve months, which puts the stock at 10.41 times sales.
What is the 52-week range for ARWR?
ARWR has traded between $37.06 and $93.10 over the past 52 weeks, and the last price is 47.0% below that high.
Is Arrowhead Pharmaceuticals, Inc. profitable?
No. Arrowhead Pharmaceuticals, Inc. is loss-making, with a net margin of -47.79% over the trailing twelve months.
What is the analyst price target for ARWR?
Wall Street analysts rate ARWR Buy, with an average price target of $101.56, 105.8% above the current price.
What sector is Arrowhead Pharmaceuticals, Inc. in?
Arrowhead Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Arrowhead Pharmaceuticals, Inc.?
Christopher R. Anzalone is the chief executive of Arrowhead Pharmaceuticals, Inc., which employs 711 people.
Where can I track ARWR in real time?
QFI Terminal shows ARWR with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ARWR live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ARWR in Terminal See plans